RA
CPRX

RFG Advisory’s Catalyst Pharmaceutical CPRX Stock Holding History

RFG Advisory’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Buy
+85,989
New +$2.54M 0.04% 300

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

RFG Advisory's CPRX Position: Q2 2026 in Review

RFG Advisory opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 85,989 shares worth $2.7M. The stake represents 0.04% of the portfolio and ranks #300 among its holdings.

36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • RFG Advisory held 85,989 shares of Catalyst Pharmaceutical worth $2.7M as of Q2 2026.
  • Catalyst Pharmaceutical was a new RFG Advisory position in Q2 2026.
  • Catalyst Pharmaceutical made up 0.04% of RFG Advisory's portfolio in Q2 2026, its #300 holding.
  • 36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.